Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.

Sajida SabsabiElio MikhaelGeorges JalkhGabrielle Macaron Mary R Rensel

Published in: Patient preference and adherence (2022)

Long-term extension and real-world studies will allow further evaluation of efficacy and safety in this population. Future research should focus on better defining SPMS, and identifying biomarkers of progression and outcome measures of treatment response in this category of patients.

Keyphrases

multiple sclerosis
clinical evaluation
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
metabolic syndrome
white matter
current status
patient reported outcomes
skeletal muscle
case control